Skip to content

Behavioral Activation for Treatment of Depression in Adolescents With Autism

Behavioral Activation for Treatment of Depression in Adolescents With Autism Spectrum Disorder: A Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05018169
Acronym
BA-A
Enrollment
18
Registered
2021-08-24
Start date
2021-08-01
Completion date
2023-08-01
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism, Depression

Brief summary

In this study, the investigators will examine the feasibility, acceptability, and preliminary efficacy of a novel, behavior-based approach for treatment of depression symptoms in adolescents with autism spectrum disorder or ASD (i.e., Behavioral Activation for Adolescents with ASD, BA-A).

Detailed description

In this study, the investigators will examine the feasibility, acceptability, and preliminary efficacy of a novel, behavior-based approach for treatment of depression symptoms in adolescents with ASD (i.e., Behavioral Activation for Adolescents with ASD, BA-A). BA-A is a 12-session manualized treatment that utilizes established behavioral activation strategies and incorporates common mental health treatment adaptations for young people with ASD. For this project, the investigators will pilot BA-A with 23 adolescents (12-17 years of age) with ASD and clinically significant depression symptoms. To investigate BA-A feasibility, the investigators will examine treatment session attendance and therapist treatment fidelity. To investigate BA-A acceptability, the investigators will utilize a mixed methods approach, inclusive of surveys and qualitative interviews, to inform BA-A protocol refinement. To investigate BA-A preliminary efficacy, the investigators will examine depression symptoms, as well as secondary outcome measures, at pre-treatment, post-treatment, and one-month follow-up.

Interventions

BEHAVIORALBA-A

Session 1 focuses on the treatment rationale, structure, and expectations, and includes psychoeducation on depression. Session 2 focuses on working with parent(s) to help them support their teen through treatment. Session 3 focuses on the (situation)/behavior/feeling cycle and how teens individuals can get trapped in a cycle of depression and inactivity. Session 4 focuses on the assessment of values and choosing preferred activities to target. Session 5 focuses on teaching skills for in-person and electronic communication. Session 6 focuses on identifying barriers to treatment success. Session 7 focuses on teaching teens to handle disagreements. Session 8 focuses on the utilization of adaptive coping skills. Sessions 9-11 are meant to be used flexibly and should include review of any challenging concepts. Session 12 is the termination session and focuses on maintaining treatment gains. Between every session, teens will track their activity for homework.

Sponsors

University of Virginia
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Previous diagnosis of ASD by a qualified health care provider * Children's Depression Inventory, Second Edition (CDI2) parent-report and/or self-report T- score ≥ 65 * Wechsler Abbreviated Scale of Intelligence, Second Edition (WASI-II) Full Scale IQ, Two-Subtest Form (FSIQ-2) ≥ 85 * Participation of a parent or legal guardian living in the same home who can read and write in English at or above the fifth grade level * Teens must have been on a stable dose of medications for mood, anxiety, or behavior for at least three months prior to enrollment and have no planned medication changes during study period * Not actively participating in another psychotherapy during study period

Exclusion criteria

* High suicide risk * Physical aggression * Psychotic and/or manic symptoms

Design outcomes

Primary

MeasureTime frame
Children's Depression Rating Scale, RevisedChange from pre-treatment to post-treatment (i.e., within one week of finishing 12-week treatment) and one-month following treatment
Children's Depression Inventory, Second Edition, Parent ReportChange from pre-treatment to post-treatment (i.e., within one week of finishing 12-week treatment) and one-month following treatment
Children's Depression Inventory, Second Edition, Self ReportChange from pre-treatment to post-treatment (i.e., within one week of finishing 12-week treatment) and one-month following treatment

Secondary

MeasureTime frame
Spence Children's Anxiety Scale, Parent ReportChange from pre-treatment to post-treatment (i.e., within one week of finishing 12-week treatment) and one-month following treatment
Spence Children's Anxiety Scale, Self ReportChange from pre-treatment to post-treatment (i.e., within one week of finishing 12-week treatment) and one-month following treatment
Social Skills Improvement System, Parent ReportChange from pre-treatment to post-treatment (i.e., within one week of finishing 12-week treatment) and one-month following treatment

Other

MeasureTime frameDescription
Treatment Fidelity ChecklistsWithin 3 months of treatment completionTreatment Fidelity Checklists will be completed by trained research assistants not involved in the implementation of the intervention.
Acceptability/Satisfaction Surveys and Interviews, Parent ReportPost-treatment (i.e., within one week of finishing 12-week treatment)
Acceptability/Satisfaction Surveys and Interviews, Self ReportPost-treatment (i.e., within one week of finishing 12-week treatment)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026